Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Closes PanVera Acquisition

NEW YORK, March 31 - Invitrogen has completed its acquisition of Vertex Pharmaceuticals subsidiary PanVera, the companies said today.

 

The $95 million cash deal, first announced in early February, will add PanVera's biochemical and cellular assay capabilities as well as proprietary reagents, probes, and proteins to Invitrogen's product portfolio.

 

Invitrogen is also acquiring PanVera's new R&D and manufacturing facility in Madison, Wis., where more than 100 PanVera employees are currently headquartered.

 

Invitrogen said it plans to expand the sale of PanVera products to target a broader market, including academic and government researchers.

 

Vertex Pharmaceuticals acquired the PanVera as part of its acquisition of Aurora Biosciences in July 2001.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.